BIOTON S.A. (WSE: BIO)
Health Care · Biotechnology · PL
zł3.87
+0.52% today · -10.5% 1Y
BIOTON S.A. (WSE: BIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $84.38M and employs 361 people.
Over the last twelve months the share price has lost 10.5%, trading between 3.43 and 4.51.
Tweenvest scores BIOTON S.A. across four factors: quality 72/100, value 79/100. Its strongest factor is value.
BIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $84.38M
- Revenue (TTM)
- $68.36M
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- 0.16
- 52-week high
- zł4.51
- 52-week low
- zł3.43
- Avg volume (3M)
- —
- Shares outstanding
- 85.86M
- Employees
- 361
- Next earnings
- —
About BIOTON S.A.
Bioton S.A. operates as a biotechnology company, engaged in the creation, production, distribution, and commercialization of a diverse array of pharmaceuticals, medicinal preparations, and active pharmaceutical ingredients. Its primary focus is on diabetes management, offering products such as recombinant human and conventional insulin, alongside oral anti-diabetic medications. The company's portfolio extends to include dietary supplements, blood glucose monitoring strips, and over-the-counter solutions for diabetics. Key insulin products include Gensulin N, Gensulin R, and Gensulin M30, available in vials and cartridges. Complementing these are advanced delivery and monitoring systems like the GensuPen 2 automatic injection device and the GensuCare glucometer for diabetes monitoring, alongside essential needles. Bioton S.A. distributes its offerings across numerous international markets, including Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. Beyond its core product activities, the company also undertakes advertising, advisory services, and general corporate management. Founded in 1989, its headquarters are situated in Ozarów Mazowiecki, Poland.
- ISIN
- PLBIOTN00029
- Founded
- 1989
- Listed since
- Mar 31, 2005
- Exchange
- Warsaw Stock Exchange
- Currency
- PLN
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Devyser Diagnostics AB (publ)OM: DVYSR | $85.81M | Skr49.75 | -2.07% |
| AnGes, Inc.TSE: 4563 | $85.64M | ¥34.00 | -2.86% |
| ReproCELL IncorporatedTSE: 4978 | $85.24M | ¥130.00 | -1.52% |
| ProMIS Neurosciences, Inc.NasdaqCM: PMN | $84.74M | $9.45 | -1.66% |
| Allied Biotech CorporationTPEX: 1780 | $84.09M | NT$24.65 | -2.76% |
| Cardiff Oncology, Inc.NasdaqCM: CRDF | $84.02M | $1.04 | -3.70% |
| 3D Global Biotech Inc.TPEX: 6808 | $83.18M | NT$34.55 | +1.62% |
| Acrivon Therapeutics, Inc.NasdaqGM: ACRV | $81.85M | $1.90 | -0.52% |
Figures last refreshed Oct 11, 2026.